1. Home
  2. FINW vs DBVT Comparison

FINW vs DBVT Comparison

Compare FINW & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FINW
  • DBVT
  • Stock Information
  • Founded
  • FINW 1999
  • DBVT 2002
  • Country
  • FINW United States
  • DBVT France
  • Employees
  • FINW N/A
  • DBVT N/A
  • Industry
  • FINW Commercial Banks
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FINW Finance
  • DBVT Health Care
  • Exchange
  • FINW Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • FINW 261.6M
  • DBVT 260.5M
  • IPO Year
  • FINW 2021
  • DBVT N/A
  • Fundamental
  • Price
  • FINW $19.48
  • DBVT $9.80
  • Analyst Decision
  • FINW Buy
  • DBVT Buy
  • Analyst Count
  • FINW 4
  • DBVT 4
  • Target Price
  • FINW $20.75
  • DBVT $14.81
  • AVG Volume (30 Days)
  • FINW 12.0K
  • DBVT 36.4K
  • Earning Date
  • FINW 10-23-2025
  • DBVT 11-05-2025
  • Dividend Yield
  • FINW N/A
  • DBVT N/A
  • EPS Growth
  • FINW N/A
  • DBVT N/A
  • EPS
  • FINW 0.96
  • DBVT N/A
  • Revenue
  • FINW $74,999,000.00
  • DBVT $3,800,000.00
  • Revenue This Year
  • FINW $52.89
  • DBVT $1,743.46
  • Revenue Next Year
  • FINW $20.66
  • DBVT $1,045.66
  • P/E Ratio
  • FINW $20.05
  • DBVT N/A
  • Revenue Growth
  • FINW 10.21
  • DBVT N/A
  • 52 Week Low
  • FINW $13.49
  • DBVT $2.21
  • 52 Week High
  • FINW $20.94
  • DBVT $12.78
  • Technical
  • Relative Strength Index (RSI)
  • FINW 58.45
  • DBVT 53.92
  • Support Level
  • FINW $19.15
  • DBVT $9.58
  • Resistance Level
  • FINW $19.80
  • DBVT $10.50
  • Average True Range (ATR)
  • FINW 0.55
  • DBVT 0.49
  • MACD
  • FINW -0.09
  • DBVT 0.07
  • Stochastic Oscillator
  • FINW 75.38
  • DBVT 61.11

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: